Since 1996, the UK's SHOT (Serious Hazards of Transfusion) hemovigilance
program has been collecting and analyzing information on UK blood transfusion adverse events and reactions.
Caspar Hogeboom, president of Cerus Europe and EEMEA stated, We believe that our extensive hemovigilance
data, clinical trial data and the demonstrated routine use of INTERCEPT with kits sold to produce almost 3 million pathogen inactivated products significantly contributed to KUH s decision to implement INTERCEPT.
Transfusion-transmitted Babesia microti identified through hemovigilance
Serious hazards of transfusion: a decade of hemovigilance
in the UK.
7) Archived donor specimens are used principally for hemovigilance
activities, including investigations of possible transfusion-transmitted infections and look-back testing.
FDA agreement to accept INTERCEPT platelet PMA based on existing portfolio of clinical and hemovigilance
Medical Center, the Netherlands) and Faber (Blood Transfusion Service, Red Cross, Luxembourg) compile 27 chapters by hematology, blood transfusion, and other specialists from Europe, North America, Asia, the Middle East, and Australia who outline safety procedures in the blood transfusion chain for those in the fields of transfusion medicine and quality and safety management, health and regulatory authorities, hospital transfusion committees, hemovigilance
officers, personnel involved in the transfusion process, hospital managers, and students.
With input from the Expert Advisory Council Grifols will continue to advance its mission of improving hemovigilance
, transfusion safety, and the quality of life for people who receive blood transfusions.
Although the use of molecular biology tests in transfusion compatibility testing is still at its early stages, its use is expected to become more widespread as a result of hemovigilance
and transfusion safety plans being introduced in many countries.
The Quebec hemovigilance
system: description and results from the first two years.
and transfusion-transmitted disease surveillance systems have not been implemented into the transfusion practice of our country.
system for monitoring adverse effects and incidents along the blood chain, including transfusion outcomes, should be established.